{"id":"W2598622099","doi":"10.1111/jdv.14237","title":"Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (<scp>UNCOVER</scp>‐1, <scp>UNCOVER</scp>‐2 and <scp>UNCOVER</scp>‐3)","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"Celgene; Regeneron Pharmaceuticals; Novartis; Amgen; Pfizer; Allergan; Biogen Idec; Eli Lilly and Company; AbbVie; Merck","keywords":"Ixekizumab; Medicine; Placebo; Etanercept; Psoriasis; Palmoplantar pustulosis; Psoriasis Area and Severity Index; Internal medicine; Plaque psoriasis; Dermatology; Gastroenterology; Psoriatic arthritis; Pathology; Tumor necrosis factor alpha; Secukinumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00191826,0.000880532,0.003173173,0.000302041,0.0003091249,0.0008626834,0.0005942981,0.001508014,0.004295642],"category_scores_gemma":[0.001850377,0.0005382444,0.002367437,0.0002866827,0.0006956888,0.0009667363,0.0002852888,0.002222037,0.000532329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005044169,"about_ca_system_score_gemma":0.0007565154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003973612,"about_ca_topic_score_gemma":0.0006078238,"domain_scores_codex":[0.9992872,0.0003953023,0.00007979633,0.0001108029,0.000052312,0.0000746469],"domain_scores_gemma":[0.9989195,0.0003963101,0.0003111335,0.00004895533,0.00004119788,0.0002828713],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9700844,0.00285361,0.0006404724,0.000511365,0.0007325489,0.00003221623,0.00004109002,0.0002272068,0.002597165,0.00004998926,0.0003910185,0.02183895],"study_design_scores_gemma":[0.8465103,0.1460355,0.004743251,0.0000605906,0.0008050858,0.00009968165,0.00002768635,0.0004839792,0.0005808654,0.0001461901,0.0004890796,0.00001779238],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807577,0.01464001,0.0003841553,0.0006321488,0.0005223535,0.0008062534,0.0005156844,0.00008816188,0.001653427],"genre_scores_gemma":[0.9938797,0.003007415,0.0004799851,0.000447049,0.0003172326,0.000605637,0.00035567,0.000009334964,0.0008979043],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004295642,"threshold_uncertainty_score":0.01437038,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02923797173096592,"score_gpt":0.2649287669594539,"score_spread":0.235690795228488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}